Dan Rudin

950 total citations
25 papers, 690 citations indexed

About

Dan Rudin is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dan Rudin has authored 25 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Hematology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dan Rudin's work include Hemophilia Treatment and Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Dan Rudin is often cited by papers focused on Hemophilia Treatment and Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Dan Rudin collaborates with scholars based in United States, Japan and Canada. Dan Rudin's co-authors include Robert Wetz, Ami Schattner, Joachim Fruebis, Alexander Kiss, Barbara A. Konkle, Amy D. Shapiro, Janice M. Staber, Doris Quon, Stacey Poloskey and Roshni Kulkarni and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Dan Rudin

24 papers receiving 664 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Rudin United States 14 194 123 114 85 70 25 690
Yuko Matsuda Japan 14 182 0.9× 76 0.6× 136 1.2× 159 1.9× 73 1.0× 48 1.1k
W.H. van der Laan Netherlands 15 91 0.5× 81 0.7× 126 1.1× 99 1.2× 168 2.4× 28 751
Julia Rey Germany 12 83 0.4× 362 2.9× 42 0.4× 96 1.1× 70 1.0× 37 865
Marcus Köller Austria 16 89 0.5× 107 0.9× 97 0.9× 92 1.1× 234 3.3× 38 857
Nicolas Batty United States 9 214 1.1× 181 1.5× 225 2.0× 15 0.2× 57 0.8× 18 744
Kyung Sook Park South Korea 14 60 0.3× 79 0.6× 165 1.4× 43 0.5× 95 1.4× 43 663
C Bologna France 19 167 0.9× 112 0.9× 64 0.6× 47 0.6× 151 2.2× 36 966
Ana Filipa Mourão Portugal 16 271 1.4× 48 0.4× 145 1.3× 83 1.0× 273 3.9× 58 983
Thomas Lund Denmark 11 202 1.0× 193 1.6× 151 1.3× 47 0.6× 20 0.3× 35 674
Prabodh Shah United States 13 145 0.7× 354 2.9× 80 0.7× 22 0.3× 73 1.0× 22 860

Countries citing papers authored by Dan Rudin

Since Specialization
Citations

This map shows the geographic impact of Dan Rudin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Rudin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Rudin more than expected).

Fields of papers citing papers by Dan Rudin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Rudin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Rudin. The network helps show where Dan Rudin may publish in the future.

Co-authorship network of co-authors of Dan Rudin

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Rudin. A scholar is included among the top collaborators of Dan Rudin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Rudin. Dan Rudin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Guowen, et al.. (2024). Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6. Blood. 144(Supplement 1). 1092–1092.
2.
Paller, Amy S., Elena Pope, Dan Rudin, et al.. (2022). A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa. Orphanet Journal of Rare Diseases. 17(1). 314–314. 6 indexed citations
3.
Tang, Jean Y., M. Peter Marinkovich, Eleanor Lucas, et al.. (2021). A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet Journal of Rare Diseases. 16(1). 175–175. 59 indexed citations
4.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2020). BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine. 383(11). 1018–1027. 95 indexed citations
5.
Li, Jing, Jun Chen, Sebastiaan J.M. Gaemers, et al.. (2019). Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1. Molecular Genetics and Metabolism. 129(2). 117–124. 12 indexed citations
6.
Banfield, Christopher, Dan Rudin, Indranil Bhattacharya, et al.. (2019). First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects. British Journal of Clinical Pharmacology. 86(4). 812–824. 21 indexed citations
7.
Nolan, Beatrice, Johnny Mahlangu, Guy Young, et al.. (2018). ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A. Blood. 132(Supplement 1). 1192–1192. 4 indexed citations
8.
Fischer, Tanya, S. Pablo Sardi, Lamya S. Shihabuddin, et al.. (2018). Evaluation of Glucosylceramide Synthase (GCS) Inhibition for GBA-Associated Parkinson’s Disease (P3.051). Neurology. 90(15_supplement). 1 indexed citations
9.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2018). BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood. 132(Supplement 1). 636–636. 13 indexed citations
10.
11.
Kim, Harold, et al.. (2017). Inadequacy of current pediatric epinephrine autoinjector needle length for use in infants and toddlers. Annals of Allergy Asthma & Immunology. 118(6). 719–725.e1. 26 indexed citations
12.
Yin, Donghua, Kerry Barker, Ruifeng Li, et al.. (2014). A randomized phase 1 pharmacokinetic trial comparing the potential biosimilarPF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01). British Journal of Clinical Pharmacology. 78(6). 1281–1290. 60 indexed citations
13.
Shaik, M. Naveed, Robert R. LaBadie, Dan Rudin, & Wendy J. Levin. (2014). Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemotherapy and Pharmacology. 74(2). 411–418. 30 indexed citations
14.
Rudin, Dan, Liang Li, Nifang Niu, Krishna R. Kalari, & Judith A Gilbert. (2011). Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. PubMed. 2(1). 1–10. 34 indexed citations
15.
16.
17.
Rudin, Dan, et al.. (2007). Somatostatin and gabexate for post‐endoscopic retrograde cholangiopancreatography pancreatitis prevention: Meta‐analysis of randomized placebo‐controlled trials. Journal of Gastroenterology and Hepatology. 22(7). 977–983. 38 indexed citations
18.
Rudin, Dan, et al.. (2007). Music in the endoscopy suite: a meta-analysis of randomized controlled studies. Endoscopy. 39(6). 507–510. 78 indexed citations
19.
Grupper, Ayelet, Dan Rudin, Benjamin Drenger, et al.. (2005). Prevention of perioperative venous thromboembolism and coronary events: differential responsiveness to an intervention program to improve guidelines adherence. International Journal for Quality in Health Care. 18(2). 123–126. 11 indexed citations
20.
Schattner, Ami, et al.. (2004). Good physicians from the perspective of their patients. BMC Health Services Research. 4(1). 26–26. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuko Matsuda Breakdown of academic impact, for papers by W.H. van der Laan Breakdown of academic impact, for papers by Julia Rey Breakdown of academic impact, for papers by Marcus Köller Breakdown of academic impact, for papers by Nicolas Batty Breakdown of academic impact, for papers by Kyung Sook Park Breakdown of academic impact, for papers by C Bologna Breakdown of academic impact, for papers by Ana Filipa Mourão Breakdown of academic impact, for papers by Thomas Lund Breakdown of academic impact, for papers by Prabodh Shah
Rankless by CCL
2026